New Epidarex $145m Fund Is A Fillip For UK Biotech
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
Scrip - January 27, 2026

2026 Japan Cell Therapy Landscape: Ventures To Gain Presence With NDAs, IPOs
While several companies await regulatory approval decisions on their cell therapies in Japan, BioCardia proceeds with discussions on an NDA filing and Innovacel readies an IPO.
Scrip - January 27, 2026

Former Zynex Execs Indicted In $873M Fraud Case
The electrostimulation pain treatment firm reportedly shipped excessive supplies to patients for eight years, driving up revenues as well as stock prices.
Medtech Insight - January 27, 2026

Growth Drug In Infant Supplements Adds To US Regulators’ Children’s Health Product Concerns
When FDA warned Agebox about selling iKids-Growth IGF-1 Support supplements as unapproved drugs, agency along with CDC had for around a month been investigating outbreak of infant botulism linked to ByHeart formula.
HBW Insight - January 27, 2026

Lupin Signs A Semaglutide Licensing Agreement With Galenicum For 23 Markets
In line with previously disclosed launch and partnering plans for GLP-1 products, Lupin shook hands with Galenicum, securing commercial rights to injectable semaglutide.
Generics Bulletin - January 26, 2026

J.P. Morgan: ANI Targets Rare Disease Pivot As Cortrophin Drives Company Past $1bn Revenue Mark
ANI’s Cortrophin Gel is benefiting from significant under-penetration in areas such as nephrology, neurology, rheumatology and pulmonology, the firm told attendees to the recent J.P. Morgan Healthcare Conference.
Generics Bulletin - January 26, 2026

Dr Reddy’s Sets Out Timelines For Orencia Biosimilar
As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.
Generics Bulletin - January 26, 2026

2026: EU MDR Review Will Give Europe Back Its Medtech Relevance
The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.
In Vivo - January 26, 2026

Beyond Viagra: How Dicot’s Novel Mechanism Could Reshape The $5bn ED Market
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
In Vivo - January 26, 2026

Fred Hassan Talks Pharma Investment Trends, Key Drivers And AI
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
In Vivo - January 26, 2026